SCAF4: A Potential Drug Target and Biomarker forSR-Related CTD

Target Name: SCAF4

NCBI ID: G57466

SCAF4

SCAF4: A Potential Drug Target and Biomarker forSR-Related CTD

SCAF4, or sulfate acetyl-CoA4, is a protein that plays a crucial role in the regulation of cell growth and differentiation. It is a key player in the cell signaling pathway known as the sonic hedgehog pathway, which is involved in the development and maintenance of tissues and organs. SCAF4 is also a potent transcriptional regulator, and has been shown to play a key role in the regulation of gene expression in a variety of cell types.

In recent years, researchers have discovered that SCAF4 plays an important role in many diseases, including cancer, neurodegenerative diseases, and immune system disorders. It is highly expressed in many tumor types and is also highly expressed in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. In addition, SCAF4 is also related to a variety of immune diseases, such as autoimmune diseases and inflammatory diseases.

SCAF4's role in many diseases goes beyond this. Studies have shown that SCAF4 regulates the G1 to S phase transition in the cell cycle and plays an important role in the S phase of the cell cycle. In addition, SCAF4 is also related to apoptosis and post-apoptotic signal transduction. These findings suggest that SCAF4 may be a potential drug target for the treatment of many tumors and other diseases.

The biological function of SCAF4 also makes it a potential biomarker. The expression level of SCAF4 can be used to predict the survival of tumor patients, and in some preclinical studies, the expression level of SCAF4 has also been used as an indicator of the efficacy of tumor treatment. In addition, because SCAF4 plays an important role in many diseases, it may also become a new therapeutic target.

Currently, researchers are exploring the use of SCAF4 in treating tumors and other diseases. Some studies are exploring the use of anti-tumor drugs to inhibit the expression of SCAF4 to improve the efficacy of the drugs. Other studies are exploring the use of SCAF4 as a biomarker to predict survival in patients with the disease and

Protein Name: SR-related CTD Associated Factor 4

Functions: Anti-terminator protein required to prevent early mRNA termination during transcription (PubMed:31104839). Together with SCAF8, acts by suppressing the use of early, alternative poly(A) sites, thereby preventing the accumulation of non-functional truncated proteins (PubMed:31104839). Mechanistically, associates with the phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit (POLR2A), and subsequently binds nascent RNA upstream of early polyadenylation sites to prevent premature mRNA transcript cleavage and polyadenylation (PubMed:31104839). Independently of SCAF8, also acts as a suppressor of transcriptional readthrough (PubMed:31104839)

The "SCAF4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCAF4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets